WallStSmart

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW) (PSNYW)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 21% more annual revenue ($3.07B vs $2.55B). WST leads profitability with a 16.1% profit margin vs -106.0%. WST earns a higher WallStSmart Score of 55/100 (C-).

PSNYW

Avoid

34

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 5.0

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for PSNYW.

WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$245.27

$176.28 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PSNYW1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
26.1%8/10

Revenue surging 26.1% year-over-year

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

PSNYW4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-292.84M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-106.0%1/10

Currently unprofitable

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : PSNYW

The strongest argument for PSNYW centers on Revenue Growth. Revenue growth of 26.1% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : PSNYW

The primary concerns for PSNYW are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

PSNYW profiles as a growth stock while WST is a mature play — different risk/reward profiles.

PSNYW carries more volatility with a beta of 1.65 — expect wider price swings.

PSNYW is growing revenue faster at 26.1% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

WST scores higher overall (55/100 vs 34/100), backed by strong 16.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

CONSUMER CYCLICAL · AUTO MANUFACTURERS · USA

Polestar Automotive Holding UK PLC (Ticker: PSNYW) is a leading contender in the electric performance vehicle market, distinguished by its commitment to innovation and sustainability. As a subsidiary of Volvo Cars and Geely, Polestar leverages cutting-edge technology and engineering to create high-performance electric vehicles, exemplified by its flagship model, the Polestar 2, which integrates exceptional design with advanced connectivity features. The company is strategically enhancing its global presence and production capabilities, positioning itself to capitalize on the rapid growth of the electric vehicle sector and play a pivotal role in the transition towards a sustainable automotive future.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?